[go: up one dir, main page]

UY28205A1 - Formulaciones farmaceuticas que comprenden un nuevo agente enmascarante de la amargura. - Google Patents

Formulaciones farmaceuticas que comprenden un nuevo agente enmascarante de la amargura.

Info

Publication number
UY28205A1
UY28205A1 UY28205A UY28205A UY28205A1 UY 28205 A1 UY28205 A1 UY 28205A1 UY 28205 A UY28205 A UY 28205A UY 28205 A UY28205 A UY 28205A UY 28205 A1 UY28205 A1 UY 28205A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical formulations
masking agent
amargura
new masking
present
Prior art date
Application number
UY28205A
Other languages
English (en)
Inventor
Hikaru Fujita
Akiko Kuroki
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY28205A1 publication Critical patent/UY28205A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

El presente invento se refiere a un nuevo agente enmascarante de la amargura para formulaciones farmacéuticas que van a aplicarse oralmente. Se encontró que ciertos tensioactivos farmacéuticamente aceptables pueden enmascarar el sabor amargo de algunos compuestos farmacéuticamente activos que saben amargos. El presente invento afecta en particular a formulaciones que comprenden epinastina o quinina.
UY28205A 2003-02-27 2004-02-25 Formulaciones farmaceuticas que comprenden un nuevo agente enmascarante de la amargura. UY28205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03004191A EP1452177A1 (en) 2003-02-27 2003-02-27 Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent

Publications (1)

Publication Number Publication Date
UY28205A1 true UY28205A1 (es) 2004-09-30

Family

ID=32748807

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28205A UY28205A1 (es) 2003-02-27 2004-02-25 Formulaciones farmaceuticas que comprenden un nuevo agente enmascarante de la amargura.

Country Status (6)

Country Link
EP (1) EP1452177A1 (es)
JP (1) JP4694468B2 (es)
AR (1) AR043412A1 (es)
PE (1) PE20041022A1 (es)
UY (1) UY28205A1 (es)
WO (1) WO2004075900A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378082B1 (en) 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
CN101129346B (zh) * 2007-07-23 2010-09-29 重庆康刻尔制药有限公司 盐酸氨溴索口腔崩解片及其制备方法
WO2010132662A1 (en) * 2009-05-13 2010-11-18 Relypsa, Inc. Powder formulations of potassium-binding active agents
WO2013121663A1 (ja) * 2012-02-14 2013-08-22 救急薬品工業株式会社 口腔内溶解型フィルム製剤
EP2962678A1 (en) * 2014-06-30 2016-01-06 Symrise AG Flavour and fragrance compositions comprising acetophenone derivatives
EP3257511B1 (en) * 2015-02-10 2018-10-24 FUJIFILM Corporation Orally disintegrating tablet and method for manufacturing same
EP3563847B1 (en) * 2016-12-28 2023-09-20 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition
WO2020035177A1 (en) 2018-08-17 2020-02-20 Symrise Ag Compositions comprising guaifenesin and eriodictyol
WO2020074073A1 (en) 2018-10-09 2020-04-16 Symrise Ag Compositions comprising guaifenesin and flavour compounds containing an isovanillyl group

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952392A (en) * 1986-03-17 1990-08-28 Peri-Oral Dental Products, Inc. Use of periwinkle in oral hygiene
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
JPH09323931A (ja) * 1996-06-04 1997-12-16 Taisho Pharmaceut Co Ltd 塩酸ロペラミド配合液剤組成物
JPH1025253A (ja) * 1996-07-12 1998-01-27 Kao Corp 苦味低減化剤及び苦味低減化法
CN1173742C (zh) * 1997-12-26 2004-11-03 山之内制药株式会社 缓释药物组合物
JP2002506876A (ja) * 1998-03-18 2002-03-05 ユニバーシティ テクノロジー コーポレーション 非晶質ポリマーを含む持続放出性組成物
JPH11302189A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 感冒用組成物
JPH11349492A (ja) * 1998-06-03 1999-12-21 Yamanouchi Pharmaceut Co Ltd 苦味を低減した経口用医薬組成物および苦味低減化方法
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
DE10152973A1 (de) * 2001-10-26 2003-05-08 Boehringer Ingelheim Int Neue trockene und wässrige Epinastin-Sirup-Formulierung

Also Published As

Publication number Publication date
JP4694468B2 (ja) 2011-06-08
EP1452177A1 (en) 2004-09-01
WO2004075900A2 (en) 2004-09-10
AR043412A1 (es) 2005-07-27
PE20041022A1 (es) 2005-01-18
JP2006519202A (ja) 2006-08-24
WO2004075900A3 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
EA200700892A1 (ru) Липосомная композиция, содержащая активное вещество для релаксации гладкой мускулатуры, получение этой композиции и ее терапевтическое применение
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
CR9609A (es) Formulaciones de una sal de bupropion de liberacion modificada
EP1246608A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
TW200716208A (en) Modified and immediate release memantine bead formulation
WO2005065646A3 (en) Novel drug compositions and dosage forms
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BRPI0407181A (pt) Formulação farmacêutica
UY28205A1 (es) Formulaciones farmaceuticas que comprenden un nuevo agente enmascarante de la amargura.
PA8529701A1 (es) Compuestos retinoides
WO2008042944A3 (en) Non-irritating oral care formulations
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
WO2006118948A3 (en) Therapeutic compositions
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
ITTO20120776A1 (it) Procedimento per mascherare l'amaro di un filtro uv
BRPI0410044B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
DE60311665D1 (de) Pharmazeutische zusammensetzungen
BRPI0416202A (pt) formulações inibidoras de fosfodiesterase v

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150514